TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with moderately severe or severe congenital haemophilia B with a factor IX activity of 2% or below according to medical records~* History of at least 150 exposure days to other factor IX products~* Patients currently treated on-demand with at least 6 bleeding episodes during the last 12 months or at least 3 bleeding episodes during the last 6 months, or patients currently on prophylaxis~Exclusion Criteria:~* Known history of factor IX inhibitors based on existing medical records, laboratory report reviews and patient and legally acceptable representative (LAR) interviews~* HIV (Human immunodeficiency virus) positive, with a viral load equal to or above 400,000 copies/mL and/or CD4+ lymphocyte count equal to or below 200/microL~* Congenital or acquired coagulation disorders other than haemophilia B~* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)~* Immune modulating or chemotherapeutic medication

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis, high dose (trial duration 52 weeks) (Type: EXPERIMENTAL): None
- Prophylaxis, low dose (trial duration 52 weeks) (Type: EXPERIMENTAL): None
- On-demand (trial duration 28 weeks) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is 18-80 years of age.~* The patient has provided written informed consent.~* The patient is scheduled for hip arthroscopy surgery for treatment of FAI~* The patient has an ASA of I, II, or III.~* The patients understands the explanation of the protocol.~Exclusion Criteria:~* The patient has history of a major GI bleeding event~* The patients has a history of renal impairment or creatinine \> 1.5~* The patient has taken NSAIDs within 48 hours of surgery or in the perioperative period~* The patient has a history of heterotopic ossification following surgery~* The patient has a hypersensitivity reaction to Naproxen~* The patient is undergoing a concomitant procedure in addition to treatment of FAI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen (Type: ACTIVE_COMPARATOR): • Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
- Placebo (Type: PLACEBO_COMPARATOR): • Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent by parent/guardian (written or oral)~* Permanent residentship in the study area~* Age of 3 months +/-4 weeks~Exclusion Criteria:~* Hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis including dark urine and/or purpura, presumptive signs of bone marrow depression such as sore throat and/or mouth ulcers)~* Other severe adverse events related to pyrimethamine-sulfadoxine application~* Signs of severe hepatic or renal dysfunction not due to malaria~* Other reasons after decision of the study physician

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 4 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* dialysis therapy for at least 2 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of any investigational drug within 4 weeks before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk renal cancer per modified UISS criteria~* Eastern Cooperative Oncology Group (ECOG) 0-2~* predominant clear cell histology~* No prior anti-cancer treatment~* Kidney tumor has been removed~* No evidence of macroscopic disease following surgery~Exclusion Criteria:~* Histologically undifferentiated carcinomas or collecting duct carcinoma, lymphoma, sarcoma or subjects with metastatic renal sites.~* Diagnosis of any second malignancy within the last 5 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months~* known HIV or Hepatitis~* any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* advanced, low-grade non-Hodgkin's and mantle cell lymphoma.~Exclusion Criteria:~* possibility of curative radiation therapy;~* secondary NHL;~* participation in another clinical trial eg with cytostatic chemotherapy or cytokines;~* concomitant diseases and/or restricted organ function precluding therapy according to the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 70 years of age.~* Hospitalization for NSTEMI or UA \< 72 hours~Exclusion Criteria:~* Contraindication to P2Y12 inhibitors i.e. clopidogrel, prasugrel or ticagrelor:~* Unable or unwilling to give informed consent or have a life expectancy of less than one year.~* Having received thrombolytic therapy within the previous 24 hours.~* Severe renal function impairment needing dialysis.~* Confirmed or persistent severe hypertension (Systolic Blood Pressure (SBP) \> 180 mmHg and/or Diastolic Blood Pressure (DBP) \>110 mmHg) at randomization.~* At increased bleeding risk, at the investigator's opinion, e.g. because of malignancy.~* Cardiogenic shock (SBP ≤ 80mmHg for \>30 mins) or Intra-Aortic Balloon Pump (IABP) at the time of screening.~* History of major surgery, severe trauma, fracture or organ biopsy within 90 days prior to randomisation.~* Clinically significant out of range values for platelet count or haemoglobin at screening, in the investigator's opinion.~* ACS under dual antiplatelet therapy, e.g. aspirin with a P2Y12 inhibitor; clopidogrel, prasugrel, ticagrelor.~* Patients with a known CYP2C19 genotype at the time of randomization.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Clopidogrel
- Control (Type: ACTIVE_COMPARATOR): Ticagrelor/Prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known cases of Idiopathic Dilated Cardiomyopathy (IDC)~* Those patients in whom heart failure medications were stable for at least 1 month~* More than 6 months aged~Exclusion Criteria:~* Recent modification in medications~* Hemodynamic instability~* Congenital heart disease~* Metabolic heart disease~* Cardiac dysfunction resulting from abnormalities in other organs and those with an acquired cardiomyopathy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Coenzyme Q10 (Type: EXPERIMENTAL): Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects.
- Placebo (Type: PLACEBO_COMPARATOR): known cases of idiopathic dilated cardiomyopathy who received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be over 18 years of age.~* Suspected or proven acute variceal bleeding , Gastric lavage will be done for all patients at admission (Acute bleeding is confirmed on the presence of blood in stomach)~* Subjects must be willing to give written informed consent for the trial~* Known or suspected cirrhosis~Exclusion Criteria:~* Patient is: \< 18 years of age~* Unable to consent~* Contraindicated to undergo endoscopy,~* Already hospitalized for another illness~* Pregnant or lactating~* Patients with altered post-surgical anatomy of the stomach~* Previously placed intrahepatic portosystemic shunt~* Patient treated by other endoscopic or surgical modalities within 30 days prior to the intended application of Hemospray

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hemospray (Type: EXPERIMENTAL): All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission).
- Non Hemospray (Type: ACTIVE_COMPARATOR): All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebivolol in Patients With Systolic Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male of female, 18 to 64 years of age at screening~* mean seated heart rate at least 60 bpm~* diagnosed systolic stage 2 hypertension~* unremarkable physical exam findings~Exclusion Criteria:~* high risk due to secondary hypertension or former stage 3 hypertension by JNC6~* concurrent conditions (reno, cardiovascular, obesity, thyroid, etc)~* currently taking medication that cannot be stopped during the course of the study~* participating other clinical trials~* member of the study center personnel~* documented drug abuse~* contra indication to beta blocker~* abnormal lab finding~* poor compliance~* other conditions judged by investigator that is not suitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Open-label, Safety and Tolerability Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who participated in 331-07-203 and who, in the opinion of the investigator, have the potential to benefit from continued administration of OPC-34712 for the treatment of schizophrenia.~2. Outpatient status at last visit of Study 331-07-203.~Exclusion Criteria:~1. Sexually active males who are not practicing two different methods of birth control during the study and for 90 days after the last dose of study medication or who will not remain abstinent during the study and for 90 days after the last dose, or sexually active females of childbearing potential who are not practicing two different methods of birth control during the study and for 30 days after the last dose of study medication or who will not remain abstinent during the study and for 30 days after the last dose. If employing birth control, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injection, birth control implant, condom, or sponge with spermicide.~2. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving open-label OPC-34712.~3. Subjects who during the course of their participation in 331-07-203 were treated in violation of the protocol or who developed ANY exclusion criteria during the course of their participation.~4. Subjects who do not continue to meet all applicable inclusion/exclusion criteria for Protocol 331-07-203 at the last visit (ie, Week 6) of Protocol 331-07-203.~5. Subjects who represent a risk of committing suicide based on an answer of Yes to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the Suicidal Ideation portion of the C-SSRS, or an answer of Yes to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior) on the Suicidal Behavior portion of the C-SSRS. A subject who has had any suicidal ideation within the last 6 months, any suicidal behaviors within the last two years, or who in the clinical judgment of the investigator presents a serious risk of suicide should be excluded from the study.~6. Subjects who would be likely to require prohibited concomitant therapy during the study.~7. Any subject who, in the opinion of the investigator, should not participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 67 Years
- Healthy Volunteers: f

Study Arms:
- Open-label OPDC-34712 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: iStart Smart for Teens for Healthy Weight Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between 13-18 years old~* have a BMI at ≥ 85th percentile, based on CDC growth chart~* own a smartphone;~* have access to a computer with internet access~* be able to read and speak English.~Exclusion Criteria:~* have acute or life-threatening disease~* not be able to engage in activities of daily living

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- fitbit ultra (Type: EXPERIMENTAL): Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
- Pedometer (Type: ACTIVE_COMPARATOR): After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatuline Predictive Factors in Acromegaly and NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent (also mandatory in case of retrospective documentation of subject data)~* Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG~Exclusion Criteria:~* The subject has already been included in this study~* Participation in an interventional trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neuroendocrine Tumours (Type: None): The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
- Acromegaly (Type: None): The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Pain After Inguinal Hernia Repair (SPAIHR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The subject will have elective ( the subject chooses, but does not have to undergo surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. Study surgery should be anticipated to be in the morning.~* Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.~* The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.~* The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.~Exclusion Criteria:~* Subjects with non elective or emergency surgery (must have the surgery no matter what), or hernia with incarceration (the trapping of abdominal contents within the hernia itself).~* Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.~* Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.

- Gender: MALE
- Minimum Age: 17 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete